Lowering apoB requires a combination of dietary changes, body fat reduction, and in most cases, medication. ApoB (apolipoprotein B) is a protein found on the surface of every particle capable of building plaque in your arteries, and each of these particles carries exactly one apoB molecule. That makes it essentially a direct count of how many harmful particles are circulating in your blood. Most guidelines recommend an apoB level below 90 mg/dL for moderate-risk individuals and below 80 mg/dL or even 70 mg/dL for those at higher cardiovascular risk.
Why ApoB Matters More Than LDL Cholesterol
Standard cholesterol tests measure the amount of cholesterol riding inside LDL particles, but they don’t tell you how many particles you actually have. This distinction matters because the cholesterol content of each particle varies significantly from person to person. Two people with identical LDL cholesterol numbers can have very different numbers of atherogenic particles, and it’s the particle count that drives risk.
The process works like this: apoB-containing particles circulate through your bloodstream and occasionally slip into the walls of your arteries. Once inside, they get trapped, depositing cholesterol and triggering the inflammatory cascade that builds plaque. The more particles in your blood, the more particles enter and get trapped. Smaller, cholesterol-depleted particles are actually worse in this regard because they bind more tightly to structures inside the artery wall. This is why someone with “normal” LDL cholesterol can still be at elevated risk if their particle count is high, something only an apoB test reveals.
Genetic studies using Mendelian randomization have confirmed that the benefit of lowering LDL cholesterol comes primarily from reducing the number of LDL particles, not the cholesterol cargo inside them. ApoB captures this directly, making it a more accurate measure of both your risk and how well your treatment is working.
ApoB Target Levels by Risk Category
Guidelines from multiple cardiology organizations converge on similar thresholds, though the exact numbers vary slightly:
- Moderate risk: below 90 mg/dL
- High risk: below 80 to 90 mg/dL
- Very high or extreme risk (existing heart disease, diabetes with complications): below 70 to 80 mg/dL
The 2026 ACC/AHA guidelines recommend checking apoB particularly when you already have heart disease, diabetes, or elevated triglycerides above 200 mg/dL. In these situations, your LDL cholesterol can look reassuringly low while your actual particle count remains elevated. An apoB test catches this gap.
Dietary Changes That Lower ApoB
Diet alone rarely produces the dramatic reductions that medications can, but it forms an important foundation, and for people with mildly elevated levels, it may be enough.
Increase Soluble Fiber
Soluble fiber binds to bile acids in your gut, forcing your liver to pull cholesterol from the bloodstream to make more. A dose-response meta-analysis of randomized controlled trials found that soluble fiber supplementation reduced apoB by roughly 45 mg/L on average. Good sources include oats, barley, psyllium husk, beans, lentils, and certain fruits like apples and citrus. Aiming for an additional 5 to 10 grams of soluble fiber per day on top of what you already eat is a reasonable starting point. Psyllium supplements make this easy to measure if whole foods alone fall short.
Reduce Saturated Fat and Refined Carbohydrates
Saturated fat increases the liver’s production of apoB-containing particles. Replacing saturated fat with unsaturated fats (olive oil, nuts, avocados, fatty fish) consistently lowers both LDL cholesterol and apoB. Refined carbohydrates and added sugars are also worth cutting because they raise triglycerides, which increases the number of triglyceride-rich apoB particles your liver produces. A Mediterranean-style eating pattern addresses both of these levers simultaneously.
Lose Visceral Fat
Visceral fat, the deep abdominal fat surrounding your organs, has a direct metabolic connection to apoB levels. Research in obese men found that reducing visceral fat decreased the liver’s secretion of VLDL apoB particles, effectively turning down the supply at its source. The correlation was specific to visceral fat loss rather than weight loss in general; the change in liver apoB secretion tracked with the change in visceral fat area, not with insulin or free fatty acid levels.
Weight loss also increased the rate at which the body clears LDL apoB particles from the bloodstream, providing a second mechanism of benefit. You don’t need to reach an ideal body weight for this to matter. Losing even 5 to 10 percent of your body weight, particularly if you carry excess fat around your midsection, can meaningfully shift apoB levels. Exercise that preferentially reduces visceral fat (moderate-intensity aerobic exercise like brisk walking, cycling, or swimming for 150 or more minutes per week) pairs well with caloric reduction.
Supplements With Evidence
Berberine, a compound found in several plants, has shown lipid-lowering effects in clinical studies. In one trial, berberine taken daily for four weeks reduced apoB by about 15 percent when used alone and by 29 percent when combined with other natural compounds including red yeast extract and policosanol. These are meaningful reductions, though the study was small (40 subjects) and short-term. Berberine appears to work partly by increasing the liver’s ability to clear LDL particles, similar in mechanism to how statins work but less potent.
Red yeast extract contains naturally occurring compounds similar to prescription statins and has its own evidence for LDL and apoB reduction. However, the active ingredient content varies widely between brands, and some products have been found to contain contaminants. If you go this route, choose a third-party tested product and be aware that it carries the same potential for side effects as a low-dose statin.
Medications for Significant Reductions
For most people with meaningfully elevated apoB, lifestyle changes alone won’t be enough to reach target levels. This is where medications become important, and the reductions they provide are substantial and well-documented.
Statins
Statins remain the first-line treatment. They work by blocking cholesterol production in the liver, which forces liver cells to pull more LDL particles out of circulation. High-intensity statin therapy typically reduces apoB by 35 to 50 percent. Because statins lower particle count (not just cholesterol content), the reduction in apoB closely tracks with the reduction in cardiovascular events seen in clinical trials.
Adding Ezetimibe
Ezetimibe blocks cholesterol absorption in the intestine. When added to a statin, it provides an additional 10 to 15 percent reduction in apoB beyond what the statin achieves alone. This combination is typically the next step when a statin at maximum tolerated dose hasn’t brought apoB to target.
PCSK9 Inhibitors
These injectable medications (given every two to four weeks) are the most powerful apoB-lowering agents currently available. They work by preventing the breakdown of LDL receptors on liver cells, dramatically increasing the liver’s ability to clear apoB particles from the blood. Clinical data shows PCSK9 inhibitors reduce apoB by 40 to 52 percent, and this is typically on top of statin therapy. They’re generally reserved for people with established cardiovascular disease, familial hypercholesterolemia, or those who can’t tolerate statins.
Bempedoic Acid
This newer oral medication blocks cholesterol synthesis through a pathway similar to statins but acts earlier in the process, which means it doesn’t cause the muscle-related side effects some people experience with statins. The latest ACC/AHA guidelines include it as an option for very high-risk patients aiming for LDL cholesterol below 55 mg/dL, used alongside other therapies.
Putting It All Together
The most effective approach layers multiple interventions. Start with the dietary changes and exercise that reduce your liver’s production of apoB particles: cut saturated fat and refined carbohydrates, add soluble fiber, and lose visceral fat if you carry excess abdominal weight. These changes provide a 10 to 20 percent reduction in apoB for most people.
If your apoB remains above target, a statin will typically cut it by another 35 to 50 percent. Adding ezetimibe brings further reduction, and PCSK9 inhibitors are available for those who need even more aggressive lowering. The key is to recheck your apoB level 6 to 8 weeks after any intervention change so you can see whether you’ve reached your target or need to add another layer. Unlike LDL cholesterol, which can be misleading in people with high triglycerides, small dense particles, or metabolic syndrome, apoB gives you a single reliable number to track your progress against.